M‐CAM expression as marker of poor prognosis in epithelial ovarian cancer

Currently available clinico–pathologic criteria provide an imperfect assessment of outcome for patients with advanced epithelial ovarian cancer (EOC). Identification of prognostic factors related to tumor biology might improve this assessment. We investigated the prognostic significance of the melanoma cell adhesion molecule (M‐CAM) in EOC. Using the same antibody, M‐CAM expression was tested by Western blotting in protein extracts and by immunohistochemestry in tissue microarrays generated from 133 consecutively resected, well characterized EOC samples. Fisher test, Kaplan–Meier method and Cox proportional hazards analysis were used to relate M‐CAM expression to clinico–pathological variables and to time to progression (TTP) and overall survival (OS). In vitro biochemical analysis showed a progressively increased M‐CAM expression from normal to malignant cells. M‐CAM protein, detected immunohistochemically, was significantly associated with advanced tumor stage, serous and undifferentiated histotype, extent of residual disease and p53 accumulation. Presence or absence of M‐CAM significantly divided patients according to their TTP (median, 22 vs. 79 months, respectively; log‐rank p = 0.001) and OS (median, 42 vs. 131 months, respectively; log‐rank p = 0.0003). In the subgroup of advanced stage patients who achieved complete response after front‐line treatment, M‐CAM expression and absence of residual disease were significantly associated with shorter TTP (p = 0.003, HR 5.25, 95% Cl 1.79–15.41 and p = 0.011, HR 3.77, 95% Cl 1.36–10.49 respectively) at the multivariate level. In the same sub‐group of patients, M‐CAM expression remained the only parameter significantly associated with OS (p = 0.005, HR 3.35, 95% Cl 1.42–6.88). M‐CAM is a marker of early relapse and poorer outcome in EOC. In particular, M‐CAM expression identifies a subgroup of front‐line therapy‐responding patients who undergo dramatic relapses, thus helping to better select patients who might benefit from new/alternative therapeutic modalities. © 2006 Wiley‐Liss, Inc.

[1]  Mattia Barbareschi,et al.  TMABoost: an integrated system for comprehensive management of tissue microarray data , 2006, IEEE Transactions on Information Technology in Biomedicine.

[2]  D. Montell,et al.  Ovarian Cancer Metastasis: Integrating insights from disparate model organisms , 2005, Nature Reviews Cancer.

[3]  Andrea Bolognesi,et al.  Internalization and recycling of ALCAM/CD166 detected by a fully human single-chain recombinant antibody , 2005, Journal of Cell Science.

[4]  D. Bell,et al.  Origins and molecular pathology of ovarian cancer , 2005, Modern Pathology.

[5]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[6]  R. Schneider,et al.  Endothelin-1 upregulates MCAM in melanocytes. , 2004, The Journal of investigative dermatology.

[7]  Luigi Marchionni,et al.  Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2 , 2004, Oncogene.

[8]  S. Canevari,et al.  CD95-Mediated Apoptosis Is Impaired at Receptor Level by Cellular FLICE-Inhibitory Protein (Long Form) in Wild-Type p53 Human Ovarian Carcinoma , 2004, Clinical Cancer Research.

[9]  M. Herlyn,et al.  Reversal of melanocytic malignancy by keratinocytes is an E-cadherin-mediated process overriding beta-catenin signaling. , 2004, Experimental cell research.

[10]  I. Shih,et al.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. , 2004, The American journal of pathology.

[11]  Gerhard Christofori,et al.  Cell adhesion and signalling by cadherins and Ig-CAMs in cancer , 2004, Nature Reviews Cancer.

[12]  Trevor Hastie,et al.  Gene expression patterns in ovarian carcinomas. , 2003, Molecular biology of the cell.

[13]  A. Sboner,et al.  [Tissue microarrays in oncology]. , 2003, Pathologica.

[14]  P. Brunet,et al.  Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alteration , 2003, Thrombosis and Haemostasis.

[15]  B. Becker,et al.  Upregulation of MCAM in primary bronchial epithelial cells from patients with COPD , 2003, European Respiratory Journal.

[16]  M. Barbareschi,et al.  High syndecan‐1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis , 2003, Cancer.

[17]  Peiyu Li,et al.  A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. , 2003, Blood.

[18]  M. Loda,et al.  CDX-2 Homeobox Gene Expression Is a Reliable Marker of Colorectal Adenocarcinoma Metastases to the Lungs , 2003, The American journal of surgical pathology.

[19]  I. Petersen,et al.  Expression of the Cell Adhesion Molecule CD146/MCAM in Non-Small Cell Lung Cancer , 2003, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

[20]  Suyun Huang,et al.  Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. , 2002, Cancer research.

[21]  A. Le Bivic,et al.  Identification of CD146 as a component of the endothelial junction involved in the control of cell-cell cohesion. , 2001, Blood.

[22]  M. Amin,et al.  Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression. , 2001, Gene.

[23]  M. Amin,et al.  Expression of a human cell adhesion molecule, MUC18, in prostate cancer cell lines and tissues , 2001, The Prostate.

[24]  M. Herlyn,et al.  Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication , 2001, Oncogene.

[25]  A. Lippold,et al.  Prognostic immunohistochemical markers of primary human melanomas , 2001, The British journal of dermatology.

[26]  G. Viale,et al.  p63, a p53 Homologue, Is a Selective Nuclear Marker of Myoepithelial Cells of the Human Breast , 2001, The American journal of surgical pathology.

[27]  Elise C. Kohn,et al.  The microenvironment of the tumour–host interface , 2001, Nature.

[28]  O. Vainio,et al.  HEMCAM/CD146 downregulates cell surface expression of beta1 integrins. , 2001, Journal of cell science.

[29]  D. Lockhart,et al.  Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Y. Bignon,et al.  Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). , 2000, International journal of oncology.

[31]  I. Shih.  The role of CD146 (Mel‐CAM) in biology and pathology , 1999, The Journal of pathology.

[32]  A. D. Dei Tos,et al.  Cyclin D3 expression in normal, reactive and neoplastic tissues , 1998, The Journal of pathology.

[33]  M. Bar‐eli,et al.  Melanoma progression–associated glycoprotein MUC18/MCAM mediates homotypic cell adhesion through interaction with a heterophilic ligand , 1997 .

[34]  J. Palazzo,et al.  The cell-cell adhesion receptor Mel-CAM acts as a tumor suppressor in breast carcinoma. , 1997, The American journal of pathology.

[35]  J. Johnson,et al.  Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. , 1997, Cancer research.

[36]  J. Johnson,et al.  Melanoma progression-associated glycoprotein MUC18/MCAM mediates homotypic cell adhesion through interaction with a heterophilic ligand. , 1997, International journal of cancer.

[37]  S. Fox,et al.  Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. , 1996, Human pathology.

[38]  Ross Ihaka,et al.  Gentleman R: R: A language for data analysis and graphics , 1996 .

[39]  Lawrence A. Donehower,et al.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 , 1995, Nature.

[40]  P. Allavena,et al.  Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy , 1989, International journal of cancer.

[41]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[42]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[43]  T E Walsh,et al.  Reporting results. , 1969, Archives of otolaryngology.

[44]  A. Satterfield,et al.  TREATMENT , 1924, California and western medicine.